Latest Ratios: P/E Ratio -4.2x · EV/EBITDA N/A · ROE -18.3%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $275M | $178M | $269M | $610M | $349M | $626M | $715M | $499M | $730M | $1.2B | $496M |
| Enterprise Value | $89M | $-8247300 | $16M | $333M | $278M | $521M | $560M | $431M | $642M | $1.1B | $386M |
| P/E Ratio → | -4.24 | — | — | 11.39 | — | — | — | 29.74 | 35.39 | 36.98 | 25.09 |
| P/S Ratio | 2.39 | 1.55 | 1.45 | 1.50 | 0.90 | 2.68 | 4.16 | 3.23 | 4.02 | 6.89 | 4.04 |
| P/B Ratio | 0.86 | 0.52 | 0.65 | 1.42 | 0.96 | 1.64 | 1.79 | 1.63 | 2.58 | 4.46 | 2.67 |
| P/FCF | — | — | 11.40 | 4.65 | — | — | — | 1018.83 | 22.30 | 48.32 | 26.95 |
| P/OCF | — | — | 9.82 | 4.31 | — | — | 123.05 | 50.92 | 18.68 | 40.88 | 21.79 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.07 | 0.08 | 0.82 | 0.72 | 2.23 | 3.26 | 2.79 | 3.53 | 6.45 | 3.15 |
| EV / EBITDA | — | — | — | 4.50 | 31.75 | 57891.88 | 159.78 | 26.37 | 14.04 | 31.58 | 18.80 |
| EV / EBIT | — | — | — | 5.92 | — | — | — | 47.88 | 16.35 | 38.87 | 25.99 |
| EV / FCF | — | — | 0.66 | 2.54 | — | — | — | 879.05 | 19.60 | 45.26 | 20.98 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.9% | 41.9% | 41.0% | 44.2% | 38.3% | 50.3% | 59.3% | 61.2% | 62.5% | 59.2% | 67.3% |
| Operating Margin | -59.2% | -59.2% | -11.1% | 13.3% | -1.4% | -5.0% | -3.4% | 5.8% | 21.6% | 16.6% | 12.1% |
| Net Profit Margin | -59.8% | -59.8% | -10.5% | 13.2% | -4.4% | -9.8% | -8.7% | 10.8% | 11.2% | 18.5% | 16.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -18.3% | -18.3% | -4.6% | 13.5% | -4.6% | -5.9% | -4.2% | 5.6% | 7.5% | 13.9% | 11.4% |
| ROA | -15.6% | -15.6% | -4.1% | 11.6% | -3.8% | -5.0% | -3.7% | 5.0% | 6.7% | 12.3% | 9.9% |
| ROIC | -32.8% | -32.8% | -9.9% | 18.2% | -1.4% | -3.4% | -1.8% | 3.1% | 15.5% | 15.9% | 15.8% |
| ROCE | -16.8% | -16.8% | -4.6% | 13.2% | -1.4% | -2.9% | -1.6% | 3.0% | 14.2% | 12.2% | 8.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | 0.18 | 1.43 | 1363.78 | 1.75 | 0.44 | — | — | — |
| Net Debt / Equity | — | -0.55 | -0.62 | -0.64 | -0.20 | -0.27 | -0.39 | -0.22 | -0.31 | -0.28 | -0.59 |
| Net Debt / EBITDA | — | — | — | -3.74 | -8.16 | -11609.78 | -44.14 | -4.19 | -1.93 | -2.13 | -5.34 |
| Debt / FCF | — | — | -10.74 | -2.11 | — | — | — | -139.78 | -2.70 | -3.06 | -5.96 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($199M) exceeds total debt ($13M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.58 | 6.58 | 9.95 | 9.77 | 4.71 | 4.40 | 6.21 | 6.86 | 7.84 | 6.88 | 9.02 |
| Quick Ratio | 5.80 | 5.80 | 8.93 | 8.57 | 3.32 | 3.62 | 5.53 | 6.16 | 7.02 | 6.28 | 8.34 |
| Cash Ratio | 5.01 | 5.01 | 8.00 | 7.35 | 1.61 | 2.25 | 4.50 | 4.78 | 5.60 | 4.84 | 6.98 |
| Asset Turnover | — | 0.29 | 0.39 | 0.84 | 0.87 | 0.51 | 0.38 | 0.44 | 0.58 | 0.56 | 0.59 |
| Inventory Turnover | 2.15 | 2.15 | 3.20 | 4.75 | 2.50 | 2.18 | 2.19 | 2.59 | 2.98 | 3.52 | 3.40 |
| Days Sales Outstanding | — | 70.46 | 46.78 | 36.16 | 66.69 | 70.79 | 82.55 | 87.23 | 69.97 | 92.90 | 58.93 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 8.8% | — | — | — | 3.4% | 2.8% | 2.7% | 4.0% |
| FCF Yield | — | — | 8.8% | 21.5% | — | — | — | 0.1% | 4.5% | 2.1% | 3.7% |
| Buyback Yield | 5.5% | 8.5% | 1.3% | 0.3% | 0.6% | 0.3% | 0.3% | 0.7% | 0.5% | 0.1% | 0.7% |
| Total Shareholder Yield | 5.5% | 8.5% | 1.3% | 0.3% | 0.6% | 0.3% | 0.3% | 0.7% | 0.5% | 0.1% | 0.7% |
| Shares Outstanding | — | $73M | $74M | $74M | $73M | $72M | $68M | $62M | $63M | $61M | $57M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OSUR stock.
OraSure Technologies, Inc.'s current P/E ratio is -4.2x. The historical average is 50.3x.
OraSure Technologies, Inc.'s return on equity (ROE) is -18.3%. The historical average is -9.1%.
Based on historical data, OraSure Technologies, Inc. is trading at a P/E of -4.2x. Compare with industry peers and growth rates for a complete picture.
OraSure Technologies, Inc. has 41.9% gross margin and -59.2% operating margin.
Key Metrics
Top Statement Risk
Imminent liquidity and solvency crisis
Metrics are mathematically derived from official filings.
Distressed Valuation Amidst Revenue Collapse
As reported in recent financial statements, OraSure's P/S ratio of 2.79 reflects a market struggling to price a business in transition, as the company's negative TTM P/E of -4.74 suggests that traditional earnings-based valuation metrics are currently disconnected from the firm's underlying operational reality.
The current valuation appears to be pricing the company as a distressed asset rather than a growth-oriented diagnostic firm. Investors should monitor whether the P/B ratio of 0.96 indicates a floor for the stock or if further asset impairments will continue to erode the book value, rendering current multiples misleading.
Capital Efficiency Decaying Into Negative Territory
Based on the company's reported figures, ROIC has deteriorated from a positive 3.3% in 2023Q4 to -8.1% by 2025Q4, signaling that the firm is currently destroying shareholder value rather than compounding it through its core diagnostic and molecular solutions investments.
The sharp decline in returns on capital suggests that the company's manufacturing-heavy infrastructure is no longer generating sufficient throughput to cover its cost of capital. This trend warrants further investigation into whether management can pivot toward higher-margin genomic products or if the current capital base is structurally misaligned.
Working Capital Management Facing Severe Friction
According to recent quarterly data, the cash conversion cycle has expanded significantly to 199,184 days in 2026Q1, a figure that highlights extreme operational friction and suggests that the company's ability to efficiently convert inventory into cash has been severely compromised by the post-pandemic demand cliff.
The dramatic spike in DSO and DIO metrics implies that the company is struggling to clear legacy inventory while simultaneously facing collection delays. This inefficiency suggests that the firm's working capital cycle is currently a major drain on liquidity, necessitating a more aggressive approach to inventory management.
Liquidity Buffer Under Extreme Stress
As indicated by the financial data, the current ratio has fluctuated wildly, reaching 5.46 in 2026Q1, yet this headline figure masks a precarious cash position that appears insufficient to support the company's ongoing operating losses and high fixed-cost structure in the absence of new financing.
While the current ratio appears high, the underlying cash and equivalents are rapidly depleting, which may indicate that the company's liquidity is tied up in potentially obsolete inventory. Investors should monitor the quick ratio closely, as it provides a more realistic view of the firm's ability to meet immediate obligations.
Misapplied Reliance on P/E Multiples
The most commonly misapplied metric for OraSure is the P/E ratio, which obscures the company's true financial health by focusing on bottom-line earnings that are currently distorted by massive non-cash charges and pandemic-related inventory write-downs that do not reflect the firm's ongoing cash-generating capacity.
Analysts should instead prioritize cash-burn analysis and the sustainability of the Molecular Solutions segment's revenue. Relying on P/E in a period of negative margins and structural restructuring leads to a fundamental misunderstanding of the company's solvency risk and its potential for a long-term turnaround.